Recent Quotes (30 days)

You have no recent quotes
chg | %

Takeda Pharmaceutical Co Ltd news

   Watch this stock
Showing stories 1 - 10 of about 123   

Articles published

4502 6,080.00 -31.00 (-0.51%)
price chart
Immunogen (IMGN), Takeda Enter Licensing Agreement Covering ADC ...
Takeda Pharmaceutical Company Limited and ImmunoGen, Inc. (Nasdaq: IMGN) announced that Takeda has licensed exclusive rights to use ImmunoGen's ADC technology - including ImmunoGen's new DNA-acting IGN payload agents - to develop and ...
Takeda Pharma licenses rights to use ImmunoGen's ADC technology  pharmabiz.com
Takeda Licenses Rights to Use ImmunoGen, Inc.'s Novel Antibody-Drug ...  MarketWatch
Amgen Granted FDA Priority Review for Expanded Use of Kyprolis
Amgen Inc. said the U.S. Food and Drug Administration granted priority review status to its supplemental new drug application for Kyprolis to treat patients with relapsed multiple myeloma who have received at least one prior therapy.
MorphoSys Nominates Three New Candidates for Supervisory Board
Dr. Frank Morich, M.D., Ph.D. was most recently Chief Commercial Officer and Member of the Board of Directors of Takeda Pharmaceutical Company Ltd., Tokyo, Japan, as well as Chief Executive Officer of Takeda Pharmaceutical International GmbH.
Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief ...
Orexigen developed Contrave� (naltrexone HCl and bupropion HCl extended release), which is approved in the United States and is being commercialized there by the company's North American partner, Takeda Pharmaceuticals. In Europe the drug has been ...
Japan drugmaker Takeda says Christophe Weber to become CEO April 1
TOKYO, March 4 (Reuters) - Takeda Pharmaceutical Co Ltd said on Wednesday that it was promoting President and Chief Operating Officer Christophe Weber to the role of chief executive officer effective April 1, replacing Yasuchika Hasegawa.
Japan drugmaker Takeda says Christophe Weber to become CEO effective April 1  Economic Times
Takeda Announces Appointment of Christophe Weber as Chief Executive Officer  The FINANCIAL
Gainers in the LimeLight: Restoration Hardware Holdings Inc (NYSE:RH), Spirit ...
The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is ...
Orexigen's Obesity Drug Mysimba Gains European Approval - Analyst Blog
Orexigen has a collaboration with Takeda Pharmaceutical Company Ltd TKPYY for Contrave in North America. As per Takeda, U.S.
Innocoll AG Secures EUR 25 Million Loan Commitment From European ...
The debt financing, which Innocoll AG entered into together with its subsidiary, Innocoll Pharmaceuticals Limited, is provided by the European Investment Bank (EIB), the long-term lending institution of the European Union owned by its Member States ...
TWi Tells Fed. Circ. Takeda's Dexilant Patent Claims Are Invalid
Law360, Washington (March 06, 2015, 2:36 PM ET) -- TWi Pharmaceuticals Inc. pressed the Federal Circuit on Friday to revive its generic version of Takeda Pharmaceutical Co. Ltd.'s acid reflux medicine Dexilant, arguing that Takeda's patent claims for ...
Form 8-K IMMUNOGEN INC For: Mar 20
On March 20, 2015, ImmunoGen, Inc. (referred to as �we,� �our� or �us�) entered into a right-to-test agreement with Takeda Pharmaceutical Company Limited through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc. The agreement provides ...